ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C26H35NO
CAS番号:
分子量:
377.56
MDL number:
NACRES:
NA.24
UNSPSC Code:
41116107
eCl@ss:
25140904
grade
pharmaceutical analytical impurity (PAI)
agency
USP
API family
abiraterone
manufacturer/tradename
USP
application(s)
pharmaceutical
pharmaceutical
pharmaceutical small molecule
format
neat
storage temp.
2-8°C
General description
Find answers to frequently asked questions on USP products in USP FAQs.
Abiraterone Ethyl Ether is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Abiraterone Acetate
Therapeutic Area: Oncology
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Abiraterone Acetate
Therapeutic Area: Oncology
Application
Abiraterone Ethyl Ether (USP PAI) is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.
Features and Benefits
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
注意喚起語
Danger
ハザードコード
Hazard Classifications
Aquatic Chronic 1 - Repr. 1B - STOT RE 2
標的臓器
Endocrine system
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
一体何が起きているの？
WGK 3
引火点 (F)
Not applicable
引火点（°C）
Not applicable